Findings

What do systematic reviews say?

99 questions · 101 findings · 13 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 48 · 47.5%GRADE not reported 20 · 19.8%Very low 18 · 17.8%Low 9 · 8.9%Moderate 6 · 5.9%High 0 · 0%

Low‐level laser therapy vs ultrasound

Overall improvement in CTS: SSS: long term Scale from: 1 to 5 · carpal tunnel syndrome

1 finding from 1 review

Low‐level laser therapy for carpal tunnel syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Low‐level laser therapy vs ultrasound

Overall improvement in CTS: FSS: long term Scale from: 1 to 5 · carpal tunnel syndrome

1 finding from 1 review

Low‐level laser therapy for carpal tunnel syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low

Corticosteroids vs placebo

Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deflazacort vs prednisone

Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Weekend‐only vs prednisone

Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Multi‐modal hand therapy vs normal activities and advice

Improvement in functional ability · people who have had carpal tunnel release surgery

1 finding from 1 review

Rehabilitation following carpal tunnel release 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

Nocturnal ventilation vs no ventilation

No improvement of hypoventilation symptoms: long‐term · patients with neuromuscular and chest wall disorders and chronic hypoventilation

It is very uncertain whether nocturnal ventilation changes no improvement of hypoventilation symptoms: long‐term compared with no ventilation (very low certainty).

1 finding from 1 review

Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders 2014 · Cochrane Headline outcomes only
RR 0.43 [0.18, 1.03]
3 studies · 51 participants
Very low

Nocturnal ventilation vs no ventilation

No improvement of daytime hypercapnia: long‐term · patients with neuromuscular and chest wall disorders and chronic hypoventilation

It is very uncertain whether nocturnal ventilation changes no improvement of daytime hypercapnia: long‐term compared with no ventilation (very low certainty).

1 finding from 1 review

Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders 2014 · Cochrane Headline outcomes only
RR 0.59 [0.41, 0.86]
3 studies · 58 participants
Very low

Volume‐cycled ventilation vs pressure‐cycled ventilation

No improvement of hypoventilation symptoms: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation

The review found no eligible studies for this question.

1 finding from 1 review

Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Volume‐cycled ventilation vs pressure‐cycled ventilation

No improvement of daytime hypercapnia: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation

The review found no eligible studies for this question.

1 finding from 1 review

Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thyrotropin‐releasing hormone tartrate vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Thyrotropin‐releasing hormone tartrate vs placebo

Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Varenicline vs placebo

Generic quality of life measures · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Very low

Varenicline vs placebo

Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Riluzole vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Riluzole vs placebo

Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Idebenone vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Idebenone vs placebo

Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Physiotherapy and occupational therapy vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Hydroxytryptophan vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported